Brind.

Soleno Therapeutics achieved FDA approval and submitted an MAA to the EMA for its drug VYKAT XR.

2 reports, 1 independent Updated Aug 7
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Soleno Therapeutics achieved FDA approval and submitted an MAA to the EMA for its drug VYKAT XR.

Who's involved

What this event is mainly about
Soleno Therapeutics (United States)FDA

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireSoleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
  • GlobeNewswireSoleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASD